Platelet-activating factor synthesized by IL-12-stimulated polymorphonuclear neutrophils and NK cells mediates chemotaxis. 1998

B Bussolati, and F Mariano, and A Cignetti, and A Guarini, and V Cambi, and R Foà, and G Piccoli, and G Camussi
Dipartimento di Discipline Medico-Chirurgiche, Università di Torino, Italy.

IL-12 is chemotactic for NK cells and polymorphonuclear neutrophils (PMN), but not for monocytes. In the present study, we evaluated whether the chemotactic effect of IL-12 is a direct phenomenon or is dependent on the generation of secondary mediators. The results obtained indicate that IL-12 induces a dose- and time-dependent synthesis of platelet-activating factor (PAF) from PMN and NK cells and of reactive oxygen radicals (ROS) from PMN. Monocytes and CD56-negative PBMC cells did not synthesize PAF or ROS after challenge with IL-12. The production of ROS by PMN was significantly inhibited by two chemically different PAF receptor antagonists (WEB 2170 and CV 3988), suggesting an autocrine stimulation of PMN by PAF newly synthesized after the challenge with IL-12. Moreover, the IL-12-induced chemotaxis of PMN and NK cells was significantly reduced by both WEB 2170 and CV 3988, suggesting that synthesized PAF mediates the chemotactic effect of IL-12. Preincubation with superoxide dismutase, which blocks the formation of superoxide anions, also reduced the chemotactic effect of IL-12 on PMN, but not on NK cells, suggesting that superoxide anion generation is relevant only for the IL-12-induced chemotaxis of PMN. In conclusion, the results of the present study indicate that IL-12-induced PAF synthesis plays a critical role in triggering the events involved in the motogenic response of PMN and NK to IL-12.

UI MeSH Term Description Entries
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D010972 Platelet Activating Factor A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION. AGEPC,Acetyl Glyceryl Ether Phosphorylcholine,PAF-Acether,Phosphorylcholine, Acetyl Glyceryl Ether,1-Alkyl-2-acetyl-sn-glycerophosphocholine,Platelet Aggregating Factor,Platelet Aggregation Enhancing Factor,Platelet-Activating Substance,Thrombocyte Aggregating Activity,1 Alkyl 2 acetyl sn glycerophosphocholine,Aggregating Factor, Platelet,Factor, Platelet Activating,PAF Acether,Platelet Activating Substance
D002634 Chemotaxis, Leukocyte The movement of leukocytes in response to a chemical concentration gradient or to products formed in an immunologic reaction. Leukotaxis,Leukocyte Chemotaxis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D017382 Reactive Oxygen Species Molecules or ions formed by the incomplete one-electron reduction of oxygen. These reactive oxygen intermediates include SINGLET OXYGEN; SUPEROXIDES; PEROXIDES; HYDROXYL RADICAL; and HYPOCHLOROUS ACID. They contribute to the microbicidal activity of PHAGOCYTES, regulation of SIGNAL TRANSDUCTION and GENE EXPRESSION, and the oxidative damage to NUCLEIC ACIDS; PROTEINS; and LIPIDS. Active Oxygen Species,Oxygen Radical,Oxygen Radicals,Pro-Oxidant,Reactive Oxygen Intermediates,Active Oxygen,Oxygen Species, Reactive,Pro-Oxidants,Oxygen, Active,Pro Oxidant,Pro Oxidants,Radical, Oxygen
D053707 Receptors, Interleukin-12 Cell surface receptors for INTERLEUKIN-12. They exist as dimers of beta 1 and beta 2 subunits. Signaling from interleukin-12 receptors occurs through their interaction with JANUS KINASES. IL-12 Receptors,Interleukin-12 Receptors,IL-12 Receptor,Interleukin-12 Receptor,Receptor, Interleukin-12,IL 12 Receptor,IL 12 Receptors,Interleukin 12 Receptor,Interleukin 12 Receptors,Receptor, IL-12,Receptor, Interleukin 12,Receptors, IL-12,Receptors, Interleukin 12
D018123 Receptors, Interleukin Cell surface proteins that bind interleukins and trigger intracellular changes influencing the behavior of cells. Interleukin Receptors,Interleukin Receptor,Receptors, Interleukins,Interleukins Receptors,Receptor, Interleukin
D018375 Neutrophil Activation The process in which the neutrophil is stimulated by diverse substances, resulting in degranulation and/or generation of reactive oxygen products, and culminating in the destruction of invading pathogens. The stimulatory substances, including opsonized particles, immune complexes, and chemotactic factors, bind to specific cell-surface receptors on the neutrophil. Activation, Neutrophil,Activations, Neutrophil,Neutrophil Activations

Related Publications

B Bussolati, and F Mariano, and A Cignetti, and A Guarini, and V Cambi, and R Foà, and G Piccoli, and G Camussi
July 1992, The Journal of biological chemistry,
B Bussolati, and F Mariano, and A Cignetti, and A Guarini, and V Cambi, and R Foà, and G Piccoli, and G Camussi
August 1989, Journal of immunology (Baltimore, Md. : 1950),
B Bussolati, and F Mariano, and A Cignetti, and A Guarini, and V Cambi, and R Foà, and G Piccoli, and G Camussi
May 1983, The Journal of biological chemistry,
B Bussolati, and F Mariano, and A Cignetti, and A Guarini, and V Cambi, and R Foà, and G Piccoli, and G Camussi
August 1992, Journal of immunology (Baltimore, Md. : 1950),
B Bussolati, and F Mariano, and A Cignetti, and A Guarini, and V Cambi, and R Foà, and G Piccoli, and G Camussi
January 1982, Advances in experimental medicine and biology,
B Bussolati, and F Mariano, and A Cignetti, and A Guarini, and V Cambi, and R Foà, and G Piccoli, and G Camussi
September 1979, Journal of immunology (Baltimore, Md. : 1950),
B Bussolati, and F Mariano, and A Cignetti, and A Guarini, and V Cambi, and R Foà, and G Piccoli, and G Camussi
July 1984, Biochemical and biophysical research communications,
B Bussolati, and F Mariano, and A Cignetti, and A Guarini, and V Cambi, and R Foà, and G Piccoli, and G Camussi
December 1984, The Journal of biological chemistry,
B Bussolati, and F Mariano, and A Cignetti, and A Guarini, and V Cambi, and R Foà, and G Piccoli, and G Camussi
August 1988, Journal of immunological methods,
B Bussolati, and F Mariano, and A Cignetti, and A Guarini, and V Cambi, and R Foà, and G Piccoli, and G Camussi
January 1991, Advances in experimental medicine and biology,
Copied contents to your clipboard!